ClinicalTrials.gg
CompletedNCT02354937Updated Aug 28, 2020

Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment

A Phase 1 interventional study of GSK1265744 30 mg in Infection, Human Immunodeficiency Virus and HIV Infections, sponsored by ViiV Healthcare. Completed at 2 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-08-28.

Primary conditionHIV InfectionsRegistry: InfectionsReclassifiedWhy we changed it
Registry
Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
HIV Infections
Why
  1. The study's listed conditions name HIV Infections, a narrower term within Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.

Enrollment
31st of 36
16 · median 200
Started
2015
with 2 others
Phase 1
10 of 36
none open now
Registered
7th of 36
by date
Lead sponsor
24 of 36
ViiV Healthcare

Among the 36 studies testing cabotegravir in HIV Infections, this one is the 31st largest by enrollment, is one of 3 that started in 2015, is one of 10 in phase 1, and was the 7th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cabotegravir

cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cabotegravir in HIV Infections, or all of them as a file.
02

Study summary

GSK1265744 (744) is an integrase strand transfer inhibitor (INSTI) currently in development for both the treatment and prevention of human immunodeficiency virus (HIV) infection. Renal elimination of unchanged 744 is extremely low, with no parent 744 detected in the urine after a single 30 mg radiolabeled dose. Despite the minimal contribution of renal clearance on overall 744 elimination, renal impairment may potentially inhibit some pathways of hepatic and gut drug metabolism and transport, and as a result may impact 744 pharmacokinetics. The current Food and Drug Administration (FDA) draft guidance for renal impairment studies suggests that a pharmacokinetic (PK) study in patients with renal impairment be conducted even for those drugs primarily metabolized or secreted in bile.

The study will be comprised of two cohorts (severe renal impairment and normal renal function) of 8 subjects each. Upon enrolment, each subject will be admitted to the study center and undergo serial PK sampling following a single dose of oral 744 30 milligrams (mg). Subjects will return to the clinic for follow-up evaluations 10-14 days after the 744 30 mg dose.

03

Conditions studied

  • Infection, Human Immunodeficiency Virus
  • HIV Infections

Keywords

  • Pharmacokinetics
  • GSK1265744
  • Severe Renal Impairment
04

In context

HIV Infections Reclassified

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

This study's enrollment of 16 is below the median of 80 across 3,492 interventional studies indexed under HIV Infections.

Browse HIV Infections studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Compared within HIV Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For Renally Impaired Subjects (Cohort 1)

  • Between 18 and 70 years of age inclusive, at the time of signing the .
  • Severe renal impairment, defined as individuals with a of \< 30 milliliter (mL)/minute (min) as determined by a 24-hour urine creatinine clearance done at screening.
  • Renally impaired subjects must have clinical laboratory test results that are considered clinically stable in the opinion of the principal investigator. Subjects with laboratory parameters outside the reference range may be included if, in the opinion of the investigator and medical monitor, these findings will not interfere with the study or introduce additional safety risk to the subject.
  • Body weight >= 50 kilograms (kg) and (BMI) within the range 19 - 38 kg/ meter (m)\^2 (inclusive)
  • Male or female A female subject is eligible to participate if she is not pregnant (as confirmed by a negative serum hCG test), not lactating. Women of must be willing to practice acceptable methods of . Pre-menopausal females defined as 12 months of spontaneous amenorrhea with one of the following: Documented tubal ligation, hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion, Hysterectomy, Bilateral Oophorectomy.
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and in this protocol.

For Healthy Subjects (Cohort 2)

  • Healthy control subjects will be matched for age +/-10 years to subjects in the renal impairment cohort but must also remain in the age range:

Between 18 and 70 years of age inclusive, at the time of signing the informed consent.

  • Healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
  • Healthy subjects are defined as individuals with a creatinine clearance >= 90 mL/min as determined by a 24-hour urine creatinine clearance done at screening.
  • Healthy control subjects will be matched for BMI +/- 25% to subjects in the renal impairment cohort but must also remain in the range of:

Body weight >=50 kg and BMI within the range 19 - 38 kg/m\^2 (inclusive)

  • Male or female A female subject is eligible to participate if she is not pregnant (as confirmed by a negative serum hCG test), not lactating. Women of child-bearing potential must be willing to practice acceptable methods of birth control. Pre-menopausal females defined as 12 months of spontaneous amenorrhea with one of the following: Documented tubal ligation, hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion, Hysterectomy, Bilateral Oophorectomy. Postmenopausal
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and in this protocol.

Exclusion criteria

Exclusion Criteria:

For Renally Impaired Subjects (Cohort 1)

  • (ALT) and >1.5x (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • Current or chronic history of liver disease (including acute or chronic and C), or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • Interval (QTc) > 480 millisecond (msec)

NOTES:

The QTc is the QT interval corrected for heart rate according to Fridericia's formula (QTcF) machine-read or manually over-read.

For purposes of data analysis, QT interval corrected for heart rate according to Bazette's formula (QTcB), QTcF, or a composite of available values of QTc will be used as specified in the Reporting and Analysis Plan (RAP).

  • Systolic blood pressure outside the range of 90-160mmHg, or diastolic blood pressure outside the range of 45-95 millimeter of mercury (mmHg), or heart rate outside the range of 50-100 beats per minute (bpm) for female subjects or 45-100 bpm for male subjects in the presence (or absence) of stabilized antihypertensive treatment.
  • Evidence of previous myocardial infarction in the past 12 months or any active cardiovascular disease that, in the opinion of the investigator, could interfere with the safety of the subject.
  • Any clinically significant conduction abnormality (not including left or right complete bundle branch block) such as atrioventricular (AV) block [Mobitz type 2 second degree or higher AV block], Wolf Parkinson White [WPW] syndrome or other aberrant pathways.
  • Sinus Pauses >3 seconds.
  • Any significant arrhythmia which, in the opinion of the principal investigator and GSK medical monitor, will interfere with the safety of the individual subject.
  • Non-sustained or sustained ventricular tachycardia (>=3 consecutive ventricular ectopic beats).
  • Signs of active infection that in the opinion of the investigator would interfere with the completion of study procedures or the safety of the subject.
  • Fluctuating or rapidly deteriorating renal function, or currently receiving hemodialysis, peritoneal dialysis, or any other renal replacement therapy or other medical procedure that serves as a surrogate for renal function. Assessment of the stability of the subject's renal function will be determined by the investigator.
  • History of renal transplant.
  • History of inflammatory bowel disease.
  • History of cholecystectomy or other gastrointestinal surgery (except appendectomy more than three months prior to study).
  • History of peptic ulceration or pancreatitis within the preceding 6 months of screening.
  • Any other medical condition (except renal impairment) which, in the judgment of the investigator and medical monitor, could jeopardize the integrity of the data derived from that subject or the safety of the subject. This includes but is not limited to any pre-existing condition that interferes with normal gastrointestinal anatomy or motility that could interfere with the absorption, metabolism, and/or excretion of the study drug.
  • The use of any concurrent prohibited medications
  • Subjects with a change in dose regimen of medically required medication within the 2 weeks prior to dosing.
  • History of regular alcohol consumption within 6 months of the study defined as:

An average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 grams (g) of alcohol: 12 ounces (360 millilitre [mL]) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.

  • Inability or unwillingness to comply with lifestyle and/or dietary restrictions
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation. In addition, if heparin is used during PK sampling, subjects with a history of sensitivity to heparin or heparin-induced thrombocytopenia should not be enrolled.
  • A pre-study screen positive for alcohol, cocaine, amphetamines, phencyclidine (PCP), and/or barbiturates. A positive drug screen is permitted if it is due to a prescribed medication, provided that medication is not a Prohibited Medication.
  • A positive test for antibody.
  • A \<15 mL/min as determined by 24-hour urine collection.
  • A clinically significant elevation in serum potassium at screening, that in the opinion of the investigator and GSK Medical Monitor will interfere with the study or introduce additional safety risk to the subject.
  • A serum sodium level =\<125 milliequivalent (mEq) /liter (L) at screening
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within 56 days.
  • The subject has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Unwillingness or inability to follow the procedures outlined in the protocol.

For Healthy Subjects (Cohort 2)

  • ALT and bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • Current or chronic history of liver disease (including acute or chronic Hepatitis B and C), or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
  • QTc > 450 msec

NOTES:

The QTc is the QT interval corrected for heart rate according to Fridericia's formula (QTcF) machine-read or manually over-read.

For purposes of data analysis, QTcB, QTcF, or a composite of available values of QTc will be used as specified in the RAP.

  • Systolic blood pressure outside the range of 90-145 mmHg, or diastolic blood pressure outside the range of 45-95mmHg or heart rate outside the range of 50-100 bpm for female subjects or 45-100 bpm for male subjects.
  • Evidence of previous myocardial infarction or any clinically significant active cardiovascular disease that, in the opinion of the investigator, could interfere with the safety of the subject.
  • Any clinically significant conduction abnormality (not including left or right complete bundle branch block) such as AV block [Mobitz type 2 second degree or higher AV block], Wolf Parkinson White [WPW] syndrome or other aberrant pathways.
  • Sinus Pauses > 3 seconds.
  • Any significant arrhythmia which, in the opinion of the principal investigator and GSK medical monitor, will interfere with the safety for the individual subject.
  • Non-sustained or sustained ventricular tachycardia (>=3 consecutive ventricular ectopic beats).
  • Signs of active infection that in the opinion of the investigator would interfere with the completion of study procedures or the safety of the subject.
  • Fluctuating or deteriorating renal function or creatinine clearance (CLCR) \< 90 mL/min (determined by 24-hour urine collection) at screening. Assessment of the stability of the subject's renal function will be determined by the investigator.
  • Subjects with a pre-existing condition interfering with normal gastrointestinal anatomy or motility, hepatic and/or renal function, that could interfere with the absorption, metabolism, and/or excretion of the study drugs.
  • History of inflammatory bowel disease.
  • History of cholecystectomy or other gastrointestinal surgery (except appendectomy more than three months prior to study).
  • History of peptic ulceration or pancreatitis within the preceding 6 months of screening.
  • The use of any concurrent prohibited medications.
  • History of regular alcohol consumption within 6 months of the study defined as:

An average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 g of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.

  • A history of regular use of tobacco- or nicotine-containing products within 30 days prior to screening.
  • Inability or unwillingness to comply with lifestyle and/or dietary restrictions
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation. In addition, if heparin is used during PK sampling, subjects with a history of sensitivity to heparin or heparin-induced thrombocytopenia should not be enrolled.
  • Presence of hepatitis B surface antigen (or positive hepatitis B core antibody with negative hepatitis B surface antibody) or positive antibody test result at any time prior to first dose of study treatment.
  • A pre-study screen positive for alcohol, cocaine, amphetamines, PCP, and/or barbiturates.
  • A positive test for HIV antibody.
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within 56 days.
  • The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Unwillingness or inability to follow the procedures outlined in the protocol.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

06

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Subjects with renal impairment

    Subjects with severe renal impairment will receive single oral dose of 744 30 mg

    Drug: GSK1265744 30 mg

  • Active comparator
    Subjects with normal renal function

    Subjects with normal renal function will receive single oral dose of 744 30 mg

    Drug: GSK1265744 30 mg

Interventions

  • White to almost white coated oval tablets with unit dose strength of 30 mg for oral administrations.

07

What researchers measure

Primary outcomes

  1. Composite of PK parameters evaluated by measurement of AUC (0-infinity) and Cmax following single oral dose.

    To compare effect of severe renal impairment on PK parameters for 744 assessed by Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC\[0-infinity\]) and Maximum observed concentration (Cmax)

    Time frame: Samples will be collected at pre-dose (within 15 minutes prior to dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 120 and 168 hours post dose.

Secondary outcomes

  1. Unbound concentration and unbound fraction in plasma of GSK1265744 at 2 and 24 hours post dose

    To evaluate impact of severe renal impairment on the plasma concentration of 744 assessed by measuring unbound concentration and unbound fraction in plasma of 744

    Time frame: Samples will be collected at 2 and 24 hours post dose.

  2. Composite of PK parameters for GSK1265744 evaluated by measurement of Plasma AUC(0-t), %AUCex, C24, t1/2, CL/F, tlag, tmax and Vz/F following a single oral dose

    To evaluate composite of PK parameters for 744 assessed by Area under the concentration-time curve from time zero (pre-dose) to the time of the last quantifiable concentration (AUC\[0-t\]), Percentage of AUC(0- infinity) obtained by extrapolation (%AUCex), Concentration observed 24-hours post dose (C24), Apparent terminal phase half-life (t1/2), Lag time before observation of drug concentrations in sampled matrix (tlag), Time of occurrence of Cmax (tmax), Apparent clearance following oral dosing (CL/F), apparent terminal phase volume of distribution (Vz/F)

    Time frame: Samples will be collected at pre-dose (within 15 minutes prior to dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 120 and 168 hours post dose.

  3. Number of participants with adverse events as measure of safety and tolerability

    To evaluate Safety and tolerability of single oral dose of 744 assessed by clinical safety data from number of participants with adverse event. Reporting of adverse event from the start of Study Treatment and until the final follow-up visit. Intensity of AEs will be categorized as mild, moderate or severe.

    Time frame: Day -1 to Day 15

  4. Safety and tolerability of single oral dose of 744 assessed by clinical laboratory tests

    To evaluate Safety and tolerability of single oral dose of 744 assessed by safety laboratory tests including Hematology, clinical chemistry, urinalysis and additional parameters

    Time frame: 14 Days

  5. Safety and tolerability of single oral dose of 744 assessed by12-Lead electrocardiogram

    To evaluate Safety and tolerability of single oral dose of 744 assessed by12-Lead Electrocardiogram (ECG).

    Time frame: 2 Days

  6. Safety and tolerability of single oral dose of 744 assessed by vital signs

    To evaluate Safety and tolerability of single oral dose of 744 assessed by vital signs. It will include temperature, systolic and diastolic blood pressure, pulse rate, and respiratory rate.

    Time frame: 14 Days

08

Study locations

2 sites
  • GSK Investigational Site
    Lakewood, Colorado 80228, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55404, United States
09

References and documents

Publications

  • Parasrampuria R, Ford SL, Lou Y, Fu C, Bakshi KK, Tenorio AR, Trezza C, Spreen WR, Patel P. A Phase I Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Adults With Severe Renal Impairment and Healthy Matched Control Participants. Clin Pharmacol Drug Dev. 2019 Jul;8(5):674-681. doi: 10.1002/cpdd.664. Epub 2019 Feb 27. PubMed 30809978 ↗

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Nov 2016, 15 months.

Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 15 months is above that.

Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2015
First posted
Feb 3, 2015
StartActual
Jul 13, 2015
Primary completionActual
Nov 1, 2016
CompletionActual
Nov 1, 2016
Last update
Aug 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02354937
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Feb 3, 2015
Start date
Jul 13, 2015
Primary completion
Nov 1, 2016
Completion
Nov 1, 2016
Last update
Aug 28, 2020

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabotegravir

Start the discussion